A workshop to review and validate the transition plan to pALD was held in Douala from February 10 to 12.

Cameroon is beginning the transition to a new fixed-dose combination, Abacavir/Lamivudine/Dolutegravir (pALD 60/30/5 mg), for children. This complete treatment, administered as a single daily dose and contained in a single pack, improves adherence compared to the separate formulations currently administered to this target population. This transition aligns with WHO guidelines and aims to eliminate pediatric AIDS by 2030. The exchanges and discussions took place in an inclusive and participatory manner, with the participation of clinical experts, MoH representatives, and civil society organizations.

National implementation will occur in two strategic phases to ensure a safe transition and the management of existing separate formulations to prevent expiration.